Navigation Links
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Date:2/12/2009

dipropionate (BDP) is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the US and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract.

In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to DOR, orBec(R) also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively.

About GI GVHD

GI GVHD is a debilitating and painful disease and constitutes an unmet medical need. It is a life-threatening condition and one of the most common causes for bone marrow and stem cell transplant failure. It is a common disorder among immunocompromised cancer patients after receiving hematopoietic cell transplantation. These procedures are being increasingly used to treat patients with leukemia and other cancers to eliminate residual disease and reduce the likelihood of relapse. Unlike organ transplants where the patient's body may reject the organ, in GVHD it is the donor cells that begin to attack the patient's (host's) body - most frequently the gastrointestinal tract, liver and skin. Patients with mild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea. If left untreated, GI GVHD can progress to ulcerations in the lining of the GI tract, and in its most severe form, can be fatal. orBec(R) represents a novel oral, locally active therapy and is intended to red
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
6. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
9. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 When head lice hits a home ... frenzy to get rid of it while keeping it from ... Gables now have the solution right in their neighborhood: ... Lice Troopers provides full spectrum head lice screening and treatment ... including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
(Date:12/25/2014)... Each year trauma accounts for approximately 42 ... across the nation (according to the Centers for ... Hospital Ambulatory Medical Care Survey collected data from ... They estimated that there were between 3.5 and 4.4 ... diagnosis of broken bone or fracture. , When ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... 05, 2008 A new study published in Journal ... sclerosis (MS) patients to determine if the disease has affected ... progression of disability. , MS affects approximately 400,000 people in ... It is the most common cause of progressive disability in ...
... Professionals to Maintain Licensing or Certification, WASHINGTON, ... for completing an American Red Cross,First Aid/CPR Class ... happen., Red Cross has been approved as ... Association for Continuing Education and,Training (IACET). The approval ...
... survey shows people living with epilepsy often miss ... continues to build on the company,s commitment to ... XR(TM) (levetiracetam),extended-release tablets, -- Keppra XR(TM) is ... Epilepsy,Franchise, ATLANTA, Nov. 5 press release, ...
... havens for healing, but the numbers tell a different ... acquire after they,ve been admitted, and hospital-related infections continue ... heart disease. , Now, a radical new high-tech software ... these infections is now catching on faster than the ...
... for Medical Equipment, Facility,Design, Building Infrastructure and ... and NEW YORK, Nov. 5 Cirrus ... to provide a wide,range of technology and ... healthcare environments., (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Use Tobacco Settlement Money to Keep Kids from ... Executive Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. ... victory for the state,s kids and health by ... reduce smoking, save lives,and lower health care costs ...
Cached Medicine News:Health News:Multiple sclerosis progression can be predicted with MRI 2Health News:American Red Cross Offering Continuing Education Credits 2Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 2Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 3Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 4Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 5Health News:Reducing epic proportions 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 3Health News:North Dakota Votes to Keep Promise to Kids by Fully Funding Tobacco Prevention 2
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 2012  Coloplast North America today announced that a federal ... Devices, Inc. (GMD) was infringing on a Coloplast Urology ... stress urinary incontinence in women. Using this approach, surgeons ... regain control of their bladder. The jury ...
... Systems (NASDAQ: DCTH ) today announced financial results ... 2012 and recent weeks.  Highlights for the ... of CE Mark approval for the second generation hemofiltration cartridge ... , Treatment of the first patient with Generation 2 ...
Cached Medicine Technology:Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc. 2Delcath Highlights First Quarter 2012 And Recent Accomplishments 2Delcath Highlights First Quarter 2012 And Recent Accomplishments 3Delcath Highlights First Quarter 2012 And Recent Accomplishments 4Delcath Highlights First Quarter 2012 And Recent Accomplishments 5Delcath Highlights First Quarter 2012 And Recent Accomplishments 6Delcath Highlights First Quarter 2012 And Recent Accomplishments 7
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: